Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870649 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3OPRK1ALDH1A1 | |
| SCHEMBL5870650 | 0.77 | CHRM2 (0.44) | SLC6A2SLC6A4SLC6A3OPRK1ALDH1A1 | |
| SCHEMBL6939247 | 0.74 | AKR1C3 (0.43) | ALDH1A1 | |
| SCHEMBL4959967 | 0.70 | ESR2 (0.46) | MAPK1 | |
| SCHEMBL17628835 | 0.69 | CHRM2 (0.45) | — | |
| SCHEMBL31694656 | 0.69 | CHRM2 (0.45) | — | |
| SCHEMBL17639926 | 0.69 | CHRM2 (0.45) | — | |
| SCHEMBL5870651 | 0.68 | CCR3 (0.49) | OPRK1ALDH1A1 | |
| SCHEMBL7412171 | 0.67 | OPRK1 (0.46) | SLC6A3OPRK1ALDH1A1 | |
| SCHEMBL30479117 | 0.67 | CHRM2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194790-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | GONG LEYI | 2006-08-31 | — | — | US | disclosed |
| US-20060189596-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | GONG LEYI | 2006-08-24 | — | — | US | disclosed |
| US-7081531-B2 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2006-07-25 | — | — | US | disclosed |
| EP-1599472-A1 | CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076448-A1 | CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-10 | — | — | WO | disclosed |
| US-20040176416-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | ROCHE PALO ALTO LLC | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189596-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | CCR3, CCR10, CCR1 | SLC6A2 2346/4885SLC6A4 2246/4885SLC6A3 1381/4885 |
| US-20040176416-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | CCR3, CCR1, CCR10 | SLC6A2 1955/4885SLC6A4 1637/4885SLC6A3 1442/4885 |
| US-20060194790-A1 | Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists | CCR3, CCR10, CCR1 | SLC6A2 1937/4885SLC6A4 1319/4885SLC6A3 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.